









Markets
/
Stocks
/
nasdaq-vyne
/

Vyne Therapeutics Inc

VYNE



View Detailed Chart

0.586USD

+0.001+0.21%

Close 12/19, 16:00（ET）Quotes delayed by 15 min

18.62MMarket Cap

LossP/E TTM



Vyne Therapeutics Inc

0.586

+0.001+0.21%

Overview Company Financials Analysis

Overview

Company

Financials

Analysis

Intraday

30m

Today

+0.21%

5 Days

+56.04%

1 Month

+68.23%

6 Months

-37.68%

Year to Date

-82.50%

1 Year

-76.56%

View Detailed Chart

TradingKey Stock Score of Vyne Therapeutics Inc

Currency: USD Updated: 2025-12-19

Key Insights

Vyne Therapeutics Inc's fundamentals are relatively very healthy, and its growth potential is significant.Its valuation is considered fairly valued, ranking 165/404 in the Biotechnology & Medical Research industry.Institutional ownership is very high.Over the past month, multiple analysts have rated it as Buy, with the highest price target at 3.25.In the medium term, the stock price is expected to trend up.The company has been performing strongly in the stock market over the past month, which is supported by its strong fundamentals and technicals.The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.

Vyne Therapeutics Inc's Score

Industry at a Glance

Industry Ranking

165 / 404

Overall Ranking

295 / 4582

Industry

Biotechnology & Medical Research

Support & Resistance

Relevant data have not been disclosed by the company yet.

Score Analysis

Current score

Previous score

Analyst Rating

Based on 4 analysts

Buy

Current Rating

3.250

Target Price

+769.45%

Upside Space

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Vyne Therapeutics Inc Highlights

StrengthsRisks

VYNE Therapeutics Inc. is a clinical-stage biopharmaceutical company focused on developing differentiated therapies to treat chronic inflammatory and immune-mediated conditions with high unmet need. Its lead program is repibresib gel (also known as VYN201), a topically administered, small-molecule pan-BD bromodomain and extra-terminal (BET) inhibitor designed as a soft drug to address diseases involving multiple, diverse inflammatory cell signaling pathways while providing low systemic exposure. Its second program is VYN202, an oral, small-molecule BD2-selective BET inhibitor. The Company has rights to research, develop and commercialize products containing BET inhibitor compounds for the treatment of any disease, disorder or condition in humans. Utilizing its InhiBET platform and through its preclinical and clinical activities, the Company is evaluating the impact that BET inhibitor compounds have on regulating pro-inflammatory cytokines.

Growing

The company is in a growing phase, with the latest annual income totaling USD 501.00K.

High Profit Growth

The company's net income leads the industry, with the latest annual income totaling USD 501.00K.

Fairly Valued

The company’s latest PE is -0.74, at a medium 3-year percentile range.

Institutional Selling

The latest institutional holdings are 8.51M shares, decreasing 9.55% quarter-over-quarter.

Held by The Vanguard

Star Investor The Vanguard holds 190.38K shares of this stock.

Higher Market Activity

The company has more investor interest, with a 20-day turnover ratio of 2.76.